Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
80M
-
Shares change
-
-2.24M
-
Total reported value, excl. options
-
$1.61B
-
Value change
-
-$51.6M
-
Put/Call ratio
-
0.2
-
Number of buys
-
66
-
Number of sells
-
-50
-
Price
-
$20.06
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q3 2023
155 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q3 2023.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80M shares
.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), FMR LLC (9.49M shares), EVENTIDE ASSET MANAGEMENT, LLC (7.81M shares), VANGUARD GROUP INC (5.24M shares), BlackRock Inc. (4.4M shares), Capital International Investors (3.13M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.72M shares), STATE STREET CORP (2.7M shares), CITADEL ADVISORS LLC (2.16M shares), and Avidity Partners Management LP (2.1M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.